Bora Pharmaceuticals Gelecekteki Büyüme
Future kriter kontrolleri 5/6
Bora Pharmaceuticals kazanç ve gelirinin sırasıyla yıllık 61.1% ve 28.4% oranında artması tahmin edilirken, EPS'nin yıllık 63.6% oranında büyümesi bekleniyor.
Anahtar bilgiler
61.1%
Kazanç büyüme oranı
63.62%
EPS büyüme oranı
| Pharmaceuticals kazanç büyümesi | 16.1% |
| Gelir büyüme oranı | 28.4% |
| Gelecekteki özkaynak getirisi | n/a |
| Analist kapsamı | Low |
| Son güncelleme | 09 Jul 2026 |
Gelecekteki son büyüme güncellemeleri
Recent updates
Anlatı Güncellemesi • Jul 09
6472: Future Earnings Assumptions And Lower P/E Will Shape Fair Value
Analysts have revised their price target on Bora Pharmaceuticals from NT$530 to NT$430, citing updated expectations for revenue growth, profit margins, and a lower future P/E assumption in their valuation work. What's in the News for Bora Pharmaceuticals Analysts cut their Bora Pharmaceuticals price target from NT$530 to NT$430, reflecting updated assumptions on revenue, profit margins, and future P/E multiples.
Anlatı Güncellemesi • Jun 25
6472: Higher Future P/E Assumptions Will Support Long Term Earnings Power
The analyst price target for Bora Pharmaceuticals has changed slightly from NT$698.22 to NT$700.86. Analysts attribute this revision to updated assumptions for revenue growth, profit margins and future P/E, which are viewed as key drivers of the new valuation.Anlatı Güncellemesi • Jun 05
6472: Revised Earnings And Margin Outlook Will Support Long Term Earnings Power
Analysts have reset their fair value estimate for Bora Pharmaceuticals from NT$741.35 to NT$698.22, reflecting updated views on revenue growth, profit margins and future P/E assumptions. What's in the News No recent news items, periodical coverage, or key developments were provided for Bora Pharmaceuticals, so there are no current events to highlight for now.Anlatı Güncellemesi • Apr 28
6472: Renewed GSK Manufacturing Agreement Will Support Long Term Earnings Power
Analysts have raised their price target on Bora Pharmaceuticals by NT$741.35, reflecting slightly higher assumptions for revenue growth, profit margins and future P/E multiples. What's in the News Bora Pharmaceuticals and GSK renewed a five year manufacturing agreement, extending GSK's access to multiple Bora sites, including the Mississauga facility acquired from GSK in 2020 and the oral solid dose site in Maple Grove, Minnesota (Key Developments).Anlatı Güncellemesi • Apr 12
6472: Renewed GSK Manufacturing Partnership Will Support Long Term Earnings Power
Analysts have adjusted their price target on Bora Pharmaceuticals to reflect updated assumptions around revenue growth of 29.12% and a profit margin of 20.96%. The implied fair value remains around NT$741.35 based on a forward P/E of 13.69.Anlatı Güncellemesi • Mar 28
6472: Renewed GSK Manufacturing Agreement Will Support Long Term Earnings Power
Analysts have inched up their price target on Bora Pharmaceuticals to NT$741.35 from NT$741.02, citing updated assumptions that combine a higher revenue growth outlook of 29.58% with a slightly stronger profit margin of 20.74% and a modestly lower future P/E of 13.69. What's in the News Bora Pharmaceuticals has scheduled a board meeting on March 11, 2026, to review the 2025 fourth quarter consolidated financial statement (Key Developments).Anlatı Güncellemesi • Mar 13
6472: Renewed GSK Manufacturing Alliance Will Drive Long Term Upside Potential
Analysts have kept their NT$741.02 price target for Bora Pharmaceuticals unchanged, pointing to stable views on fair value, discount rate, revenue growth assumptions, profit margins, and future P/E as the key reasons for maintaining their stance. What's in the News Bora Pharmaceuticals and GSK renewed a five year manufacturing partnership, extending their existing relationship and broadening GSK access to multiple Bora sites, including the oral solid dose facility in Maple Grove, Minnesota (Key Developments).Anlatı Güncellemesi • Feb 26
6472: Renewed GSK Partnership And Corealis Alliance Will Support Future Upside
Analysts have kept their NT$741.02 price target for Bora Pharmaceuticals unchanged, citing largely stable assumptions on the discount rate, revenue growth, profit margin, and a slightly lower future P/E multiple. What's in the News Bora Pharmaceuticals and GSK renewed a five year manufacturing partnership, which gives GSK access to multiple Bora sites, including the Mississauga facility acquired from GSK in 2020 and a newer oral solid dose site in Maple Grove, Minnesota (Key Developments).Anlatı Güncellemesi • Feb 11
6472: Corealis Alliance Will Support Future Upside Through End To End Development
Analysts have modestly adjusted their price target on Bora Pharmaceuticals to reflect updated assumptions around discount rate, revenue growth, profit margin and future P/E. This has resulted in a refreshed fair value estimate of about NT$741.02 per share.Anlatı Güncellemesi • Jan 28
6472: Corealis Alliance Will Drive Future Upside Through Integrated Development Path
Analysts have trimmed their price target for Bora Pharmaceuticals to reflect a fair value update to $741.02 from $788.87, citing slightly adjusted revenue growth assumptions, a modestly higher profit margin outlook, and a lower future P/E input in their models. What's in the News Bora Pharmaceuticals Co., Ltd.Anlatı Güncellemesi • Jan 11
6472: Corealis Alliance Will Support Future Upside Through Streamlined Development
Analysts have kept their price target for Bora Pharmaceuticals broadly unchanged at about $789, reflecting consistent assumptions on discount rate, revenue growth, profit margin and future P/E, and indicating that recent research has not materially shifted their valuation view. What's in the News Bora Pharmaceuticals Co., Ltd.Anlatı Güncellemesi • Dec 20
6472: Alliance With Corealis Will Support Stronger Long Term Performance
Analysts have modestly reiterated their outlook on Bora Pharmaceuticals, keeping the fair value estimate steady at $788.87 per share, as they see no material changes to projected revenue growth, margins, or valuation multiples. What's in the News Bora Pharmaceuticals and Corealis Pharma formed a strategic alliance to deliver integrated end to end oral solid dose development and manufacturing services, giving clients a single pathway from early formulation through commercial production (company announcement) The partnership combines Bora's global commercial infrastructure with Corealis' formulation and clinical scale manufacturing expertise, aiming to accelerate timelines and reduce complexity for biotech and pharma innovators (company announcement) Bora and Corealis will align project management and quality systems across the drug development lifecycle to lower outsourcing risk and improve reliability from discovery through commercial launch (company announcement) Valuation Changes Fair Value Estimate is unchanged at NT$788.87 per share, indicating no revision to Bora Pharmaceuticals' intrinsic value assessment.Anlatı Güncellemesi • Dec 06
6472: Improved Profit Margins Will Support Stronger Long Term Performance
Narrative Update Analysts have nudged their price target on Bora Pharmaceuticals slightly higher to approximately $789 per share, reflecting modestly improved long term profit margin expectations, even though projected revenue growth has been tempered slightly. Valuation Changes Fair Value Estimate: unchanged at approximately NT$788.87 per share, indicating no material revision to the intrinsic value assessment.Anlatı Güncellemesi • Nov 21
6472: Improved Profit Margins Will Drive Stronger Performance Ahead
Analysts have lowered their price target for Bora Pharmaceuticals from $872.67 to $788.87. This adjustment is due to reduced revenue growth expectations, which are partially offset by projections of improved profit margins and a lower forward price-to-earnings ratio.Anlatı Güncellemesi • Sep 28
US CDMO Expansion And Specialty Focus Will Strengthen Position
The consensus analyst price target for Bora Pharmaceuticals has been revised upward, primarily driven by a significant increase in the company's expected future P/E multiple, with the fair value rising from NT$847.46 to NT$872.67. What's in the News Bora Pharmaceuticals is making significant investments to expand manufacturing and packaging capabilities at its Maple Grove, Minnesota facility, acquired via the $210 million Upsher-Smith Laboratories deal in 2024.Yeni Anlatı • Jul 20
US Facility Modernization Will Secure Future Specialty Success
Strategic shift to high-value CDMO services and facility upgrades has improved margins, driven growth, and positioned the company for market share gains.Analiz Makalesi • Mar 30
Cautious Investors Not Rewarding Bora Pharmaceuticals Co., LTD.'s (TWSE:6472) Performance Completely
With a median price-to-earnings (or "P/E") ratio of close to 20x in Taiwan, you could be forgiven for feeling...Analiz Makalesi • Jan 20
We Think Bora Pharmaceuticals (TWSE:6472) Can Stay On Top Of Its Debt
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analiz Makalesi • Nov 21
Bora Pharmaceuticals' (TWSE:6472) Earnings Are Weaker Than They Seem
Bora Pharmaceuticals Co., LTD.'s ( TWSE:6472 ) robust earnings report didn't manage to move the market for its stock...Analiz Makalesi • Oct 04
Does Bora Pharmaceuticals (TWSE:6472) Deserve A Spot On Your Watchlist?
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Analiz Makalesi • Jul 18
Investors Appear Satisfied With Bora Pharmaceuticals Co., LTD.'s (TWSE:6472) Prospects
Bora Pharmaceuticals Co., LTD.'s ( TWSE:6472 ) price-to-earnings (or "P/E") ratio of 34.2x might make it look like a...Analiz Makalesi • Jun 13
Is Bora Pharmaceuticals Co., LTD. (TWSE:6472) Trading At A 44% Discount?
Key Insights The projected fair value for Bora Pharmaceuticals is NT$1,369 based on 2 Stage Free Cash Flow to Equity...Analiz Makalesi • Apr 10
Bora Pharmaceuticals Co., LTD. (TWSE:6472) Stock Rockets 33% As Investors Are Less Pessimistic Than Expected
Bora Pharmaceuticals Co., LTD. ( TWSE:6472 ) shareholders have had their patience rewarded with a 33% share price jump...Analiz Makalesi • Apr 08
Bora Pharmaceuticals (TWSE:6472) Could Easily Take On More Debt
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analiz Makalesi • Mar 14
Shareholders Can Be Confident That Bora Pharmaceuticals' (TWSE:6472) Earnings Are High Quality
Even though Bora Pharmaceuticals Co., LTD. ( TWSE:6472 ) posted strong earnings, investors appeared to be underwhelmed...Kazanç ve Gelir Büyüme Tahminleri
| Tarih | Gelir | Kazançlar | Serbest Nakit Akışı | Faaliyetlerden Nakit | Avg. Analist Sayısı |
|---|---|---|---|---|---|
| 12/31/2027 | 30,575 | 5,495 | 3,211 | 3,869 | 3 |
| 12/31/2026 | 23,067 | 3,557 | -752 | 27 | 5 |
| 3/31/2026 | 18,536 | 1,682 | 2,707 | 3,775 | N/A |
| 12/31/2025 | 19,014 | 4,383 | 3,531 | 4,504 | N/A |
| 9/30/2025 | 19,278 | 4,419 | 2,083 | 3,051 | N/A |
| 6/30/2025 | 19,499 | 5,303 | 3,833 | 4,561 | N/A |
| 3/31/2025 | 19,049 | 6,141 | 494 | 1,108 | N/A |
| 12/31/2024 | 17,427 | 4,116 | 293 | 980 | N/A |
| 9/30/2024 | 15,508 | 4,252 | 1,827 | 2,379 | N/A |
| 6/30/2024 | 13,556 | 3,282 | -572 | 1,014 | N/A |
| 3/31/2024 | 12,277 | 2,707 | 2,306 | 3,871 | N/A |
| 12/31/2023 | 14,200 | 3,030 | 3,183 | 4,614 | N/A |
| 9/30/2023 | 16,293 | 2,868 | 2,848 | 4,257 | N/A |
| 6/30/2023 | 15,942 | 2,704 | 4,038 | 4,362 | N/A |
| 3/31/2023 | 14,158 | 2,252 | 3,684 | 3,926 | N/A |
| 12/31/2022 | 10,494 | 1,392 | 1,810 | 2,010 | N/A |
| 9/30/2022 | 6,346 | 1,128 | 1,322 | 1,465 | N/A |
| 6/30/2022 | 4,811 | 697 | 844 | 1,029 | N/A |
| 3/31/2022 | 4,650 | 594 | 1,079 | 1,389 | N/A |
| 12/31/2021 | 4,900 | 750 | 873 | 1,237 | N/A |
| 9/30/2021 | 4,418 | 1,045 | 636 | 975 | N/A |
| 6/30/2021 | 3,626 | 963 | 286 | 603 | N/A |
| 3/31/2021 | 2,794 | 868 | -261 | -43 | N/A |
| 12/31/2020 | 1,800 | 578 | 26 | 178 | N/A |
| 9/30/2020 | 1,523 | 191 | -608 | 188 | N/A |
| 6/30/2020 | 1,513 | 232 | -317 | 415 | N/A |
| 3/31/2020 | 1,521 | 262 | -211 | 478 | N/A |
| 12/31/2019 | 1,529 | 305 | N/A | 232 | N/A |
| 9/30/2019 | 1,517 | 355 | N/A | 449 | N/A |
| 6/30/2019 | 1,492 | 283 | N/A | 373 | N/A |
| 3/31/2019 | 1,515 | 267 | N/A | 318 | N/A |
| 12/31/2018 | 1,372 | 443 | N/A | 167 | N/A |
| 9/30/2018 | 1,107 | 351 | N/A | -40 | N/A |
| 6/30/2018 | 846 | 330 | N/A | -218 | N/A |
| 3/31/2018 | 525 | 274 | N/A | -263 | N/A |
| 12/31/2017 | 358 | 14 | N/A | 20 | N/A |
| 9/30/2017 | 323 | 17 | N/A | 2 | N/A |
| 6/30/2017 | 297 | 22 | N/A | 22 | N/A |
| 3/31/2017 | 291 | 24 | N/A | 5 | N/A |
| 12/31/2016 | 283 | 25 | N/A | -18 | N/A |
| 9/30/2016 | 273 | 23 | N/A | -20 | N/A |
| 6/30/2016 | 260 | 18 | N/A | -22 | N/A |
| 3/31/2016 | 247 | 26 | N/A | -4 | N/A |
| 12/31/2015 | 238 | 34 | N/A | 9 | N/A |
| 9/30/2015 | 236 | 30 | N/A | 18 | N/A |
Analist Gelecek Büyüme Tahminleri
Kazançlar ve Tasarruf Oranları: 6472 'nin tahmini kazanç büyümesi (yıllık 61.1% ) tasarruf oranının ( 1.3% ) üzerindedir.
Kazançlar ve Piyasa: 6472 şirketinin kazançlarının (yıllık 61.1% ) TW pazarından (yıllık 25.7% ) daha hızlı büyümesi öngörülüyor.
Yüksek Büyüme Kazançları: 6472 şirketinin kazançlarının önümüzdeki 3 yıl içerisinde önemli ölçüde artması bekleniyor.
Gelir ve Pazar: 6472 şirketinin gelirinin (yıllık 28.4% ) TW pazarından (yıllık 19.6% ) daha hızlı büyümesi öngörülüyor.
Yüksek Büyüme Geliri: 6472 şirketinin gelirinin (yıllık 28.4% ) yıllık 20% dan daha hızlı büyümesi öngörülüyor.
Hisse Başına Kazanç Büyüme Tahminleri
Gelecekteki Özkaynak Getirisi
Gelecekteki ROE: 6472 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok
Büyüyen şirketleri keşfedin
Şirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/07/15 20:01 |
| Gün Sonu Hisse Fiyatı | 2026/07/15 00:00 |
| Kazançlar | 2026/03/31 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Bora Pharmaceuticals Co., Ltd. 8 Bu analistlerden 5, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Chenghsin Lin | J.P. Morgan |
| Yang Huang | J.P. Morgan |
| Hsuan Chen | KGI Securities Co. Ltd. |